Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed® Versus Placebo

Sinjari, Bruna; Feragalli, Beatrice; Cornelli, Umberto; Belcaro, G; Vitacolonna, Ester; Santilli, Manlio; Rexhepi, Imena; D’Addazio, Gianmaria; Zuccari, Francesca; Caputi, Sergio

doi:10.3390/jcm9072196

Cited by 21 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, it has been shown that xerostomia can also be induced by different drug therapies such as: antidepressants, antipsychotics, anticholinergics, antihypertensives, antihistamines, and sedatives [ 33 ]. Furthermore, there is strong evidence that xerostomia is very common in diabetic patients and may be present in >50% of cases, and recently it was reported that the use of artificial saliva spray was shown to be effective in the treatment of xerostomia in type 1 and type 2 diabetes [ 34 , 35 ]. However, in our study, only 15% of patients were affected by diabetes (not specified if type 1 or type 2).…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 and Oral Manifestation: An Observational, Human Study

Sinjari

D’Ardes

Santilli

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

The correlation between SARS-CoV-2 and oral manifestations is still controversial. The aim of this observational study was to determine the oral manifestation of the hospitalized patients for COVID-19. A total of 20 patients met the inclusion criteria and gave their signed informed consent. A questionnaire of 32 questions regarding the oral and systemic health condition was administrated to these patients during the convalescence. A descriptive statistic was performed. Data were analysed through the use of χ2 test, to assess the statistical significance. A statistically significant increase of about 30% of reporting xerostomia during hospitalization was observed (p = 0.02). Meanwhile, a decrease of oral hygiene was observed during the hospitalization, even if a non-statistically significant difference was shown between the two study time points (before and after hospitalization). During the hospitalization period, 25% of patients reported impaired taste, 15% burning sensation, and 20% difficulty in swallowing. An interesting result was that among the systemic conditions, hypertension was observed in 39% of patients and mostly in female patients (62.5%). Further studies are necessary to better understand the symptoms of this new virus in order to faster detect its presence in humans. Probably, a multidisciplinary team following the COVID-19 patients could be of key importance in treating this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 and Oral Manifestation: An Observational, Human Study

Sinjari

D’Ardes

Santilli

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Clinical trials involving cisplatin, melatonin, and/or levocarnitine still hold the promise for better outcomes in the prevention and treatment of xerostomia. In addition, for disease conditions such as diabetes mellitus causing salivary gland dysfunction which results in salivary flow reduction and a change in saliva composition, significant mitigation of subjective xerostomia may be achieved through artificial saliva [ 52 ].…”

Section: Discussionmentioning

confidence: 99%

A Computational Text Mining-Guided Meta-Analysis Approach to Identify Potential Xerostomia Drug Targets

Beckman

Brennan

Igba

et al. 2022

JCM

View full text Add to dashboard Cite

Xerostomia (subjective complaint of dry mouth) is commonly associated with salivary gland hypofunction. Molecular mechanisms associated with xerostomia pathobiology are poorly understood, thus hampering drug development. Our objectives were to (i) use text-mining tools to investigate xerostomia and dry mouth concepts, (ii) identify associated molecular interactions involving genes as candidate drug targets, and (iii) determine how drugs currently used in clinical trials may impact these genes and associated pathways. PubMed and PubMed Central were used to identify search terms associated with xerostomia and/or dry mouth. Search terms were queried in pubmed2ensembl. Protein–protein interaction (PPI) networks were determined using the gene/protein network visualization program search tool for recurring instances of neighboring genes (STRING). A similar program, Cytoscape, was used to determine PPIs of overlapping gene sets. The drug–gene interaction database (DGIdb) and the clinicaltrials.gov database were used to identify potential drug targets from the xerostomia/dry mouth PPI gene set. We identified 64 search terms in common between xerostomia and dry mouth. STRING confirmed PPIs between identified genes (CL = 0.90). Cytoscape analysis determined 58 shared genes, with cytokine–cytokine receptor interaction representing the most significant pathway (p = 1.29 × 10−23) found in the Kyoto encyclopedia of genes and genomes (KEGG). Fifty-four genes in common had drug interactions, per DGIdb analysis. Eighteen drugs, targeting the xerostomia/dry mouth PPI network, have been evaluated for xerostomia, head and neck cancer oral complications, and Sjögren’s Syndrome. The PPI network genes IL6R, EGFR, NFKB1, MPO, and TNFSF13B constitute a possible biomarker signature of xerostomia. Validation of the candidate biomarkers is necessary to better stratify patients at the genetic and molecular levels to facilitate drug development or to monitor response to treatment.

show abstract

“…Despite this high prevalence, studies that examined treatment options specific for diabetes‐induced xerostomia were found to be relatively scarce. In fact, up to the authors' knowledge, only one clinical trial was performed in 2020 by Sinjari et al (2020), in which the activity of an artificial saliva spray (Aldiamed® spray) was tested in comparison to a placebo spray for the management of xerostomia in patients with DM.…”

Section: Discussionmentioning

confidence: 99%

Effect of 1% malic acid spray on diabetes mellitus‐induced xerostomia: A randomized clinical trial

et al. 2022

View full text Add to dashboard Cite

ObjectiveTo evaluate the effectiveness of topical sialogogue spray containing 1% malic acid in the treatment of xerostomia in patients with type 2 diabetes mellitus.Material and MethodsA randomized double‐blind controlled clinical trial was conducted on 52 patients with type 2 diabetes mellitus suffering from xerostomia. Patients were assigned equally to test group who received a topical sialogogue spray containing 1% malic acid and control group who received a placebo spray. Both groups were instructed to use the spray on demand for 2 weeks. The Summated Xerostomia Inventory‐Dutch Version questionnaire (SXI‐D) and the unstimulated salivary flow rate were evaluated for all patients at baseline, 2 and 4 weeks after malic acid/placebo application.ResultsAt 2 week's follow‐up, the unstimulated salivary flow rate increased significantly from 0.059 ± 0.024 to 0.191 ± 0.064 and from 0.055 ± 0.026 to 0.078 ± 0.032 for test and control groups, respectively, with a statistically significant difference favoring the test group. SXI‐D scores showed a significant decrease from 10.73 ± 2.22 to 8.38 ± 2.28 in the test group (p < 0.05), while in the control group it decreased from 10.62 ± 1.75 to 10.23 ± 1.48 (p > 0.05).ConclusionA sialogogue spray containing 1% malic acid increased the unstimulated salivary flow rate in patients with type 2 diabetes mellitus suffering from xerostomia.

show abstract

Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed® Versus Placebo

Cited by 21 publications

References 44 publications

SARS-CoV-2 and Oral Manifestation: An Observational, Human Study

SARS-CoV-2 and Oral Manifestation: An Observational, Human Study

A Computational Text Mining-Guided Meta-Analysis Approach to Identify Potential Xerostomia Drug Targets

Effect of 1% malic acid spray on diabetes mellitus‐induced xerostomia: A randomized clinical trial

Contact Info

Product

Resources

About